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Summary:
Major ABO incompatibility in stem cell transplant
recipients has been associated with pure red cell aplasia
(PRCA). Reduction of incompatible isohaemagglutinin
titres pre-transplant by various methods has been thought
to reduce the incidence of PRCA. Our data suggest that
pre-transplant reduction of incompatible isohaemaggluti-
nin titres by donor group plasma infusion does not reduce
the incidence of PRCA. We also failed to find any
relationship between pre-transplant ABO isohaemagglu-
tinin titre and the risk of developing PRCA.
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The ABO blood group system is of critical importance
in transfusion medicine, but has a less dramatic impact
on haematopoietic transplantation.1,2 ABO antigens are
potently immunogenic and are expressed on multiple
tissues in addition to red blood cells.3 Since ABO and
human leukocyte antigens (HLA) are inherited indepen-
dently, ABO incompatibility may occur in 20–40% of
HLA-matched allogeneic haematopoietic stem cell trans-
plants (SCT).2 Graft failure does not occur with increased
frequency, and most studies indicate that the incidence of
graft-versus-host disease (GVHD) is not increased follow-
ing ABO-incompatible transplants.2,4–6
Major ABO incompatibility in SCTs, defined as incom-
patibility of donor ABO antigens with the recipient’s
immune system, has been associated with pure red cell
aplasia (PRCA) following conventional myeloablative
conditioning.7–11 The proposed risks for PRCA in this
setting include the use of cyclosporine (CsA) as GVHD
prophylaxis,7,8 high initial or persistently elevated host
antidonor isohaemagglutinin levels,7,10 and RBC incom-
patibility involving donor A antigens.10,11 Reduction of
incompatible isohaemagglutinin titres prior to transplant,
either by plasma exchange, immunoadsorption or donor-
type RBC infusion, has been utilized in the past.2–14
However, this practice has been highly variable and there
are no specific recommendations. In addition, limited data
suggest that this reduction in pre-transplant titres also
reduces the incidence of PRCA.15
We have been using a relatively unusual and rarely
reported form of isoagglutinin reduction for major ABO-
mismatched SCTs. Donor group plasma is infused prior to
transplant in order to reduce the incompatible titres in
ABO-mismatched transplants, in addition to RBC deple-
tion to prevent severe hemolytic reaction at the time of
marrow transfusion.12,16–21 Hence, we carried out a retro-
spective analysis to determine whether the reduction in
titres reduced the incidence of PRCA.
Patients and methods
We undertook a retrospective analysis to study the
incidence of PRCA in 357 patients who had undergone
372 allogeneic transplants between 1986 and 2003 at our
centre. Of these, 83 were major ABO-mismatched trans-
plants. The bone marrow harvest was RBC depleted in all
patients who underwent bone marrow transplantation
(BMT) in contrast to patients who underwent peripheral
blood stem cell transplantation (PBSCT), where no such
manipulation of the graft was undertaken. RBC depletion
was carried out using hydroxyethyl starch sedimentation or
apheresis.22–24 Red cell volumes post RBC depletion were
not documented. All recipients with incompatible isohae-
magglutinin titres above 1:64 were infused with donor
group plasma at a dose of 10–15ml/kg/day for 4 days prior
to transplant in order to reduce the incompatible titres.
Incompatible titres were monitored pre-transplant and
post-infusion of donor group plasma. Titres were estimated
by saline agglutination and the indirect antiglobulin test
(IAT) using the same assay system. PRCA was defined as
the presence of delayed RBC recovery with a reticulocyte
count below 1%, after neutrophil and platelet engraftment,
defined as an absolute neutrophil count4500/mm3 and an
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unsupported platelet count 420 000/mm3. Bone marrow
examination was undertaken in the initial few patients to
document PRCA, but a falling haemoglobin with a low
reticulocyte count and normal white cell and platelet counts
with complete donor chimerism, in the setting of an ABO-
mismatched transplant, were considered adequate for the
diagnosis of PRCA.
Results
Between 1986 and 2003 there were 83 (22%) major ABO-
mismatched transplants at our centre. There were 53 males
(64%) and 30 females (36%) with an average age of 18.5
years (range: 3–51). There were 70 (84%) bone marrow
(BM) and 13 (16%) peripheral blood stem cell (PBSC)
transplants. The bone marrow harvest was RBC depleted in
all patients. In all, 54 patients with baseline titres greater
than 1:64 were given donor group plasma at a mean dose of
45ml/kg (range: 12–128). There were no reactions to donor
group plasma infusion in any patient. One patient
developed intravascular haemolysis on the day of marrow
infusion, but recovered with hydration and steroids.
PRCA developed in 15/83 patients (18%) at a mean
duration of 61 days post-transplant (range: 40–95), and
lasted for a mean duration of 3.6 months (range: 1–12).
There were eight males and seven females with an average
age of 22 years (range 5–51). The harvest was bone marrow
in 10 and peripheral blood stem cells in five. The median
major saline agglutination and IAT-incompatible titres
were 1:128 (range: 2–512) and 1:512 (range: 4–2048) in the
PRCA group when compared to 1:128 (range: 4–1024) and
1:256 (range: 16–2048) in the non-PRCA group. The
reduction in the saline agglutination and IAT titres after
infusion of donor group plasma was by two dilutions to
1:32 (range 2–128) and one dilution to 1:256 (range 4–1024)
in the PRCA group. In comparison, in the non-PRCA
group, the reduction in titres was similar by two dilutions
to 1:32 (range 2–1024) and one dilution to 1:128 (range
4–2048). In all, 45/68 patients (66%) had received donor
group plasma to reduce incompatible titres in the non-
PRCA group, while 9/15 patients (60%) received donor
group plasma in the PRCA group. This difference was not
statistically significant. The average volume of incompa-
tible plasma infused was 47ml/kg (range: 21–70) in the
PRCA group and 44ml/kg (range: 12–128) in the non-
PRCA group (Table 1). Out of the 15 patients who
developed PRCA, 12 were treated with prednisolone for a
mean duration of 4.4 months (range: 1–9) in addition to
CsA. Prednisolone was added in patients who developed
PRCA while taking CsA. The average units of RBC
transfused were 3.6 (range: 1–9). The time of initiation of
RBC transfusion ranged from 1.5 to 3 months, with a mean
of 2 months post-transplant. The mean time to recovery
was 3.5 months, with a maximum of 12 months. All
patients have recovered from PRCA. The incidence of
PRCA was higher in the PBSC group when compared to
the BM group, but this was not statistically significant
(P¼ 0.057) using the w2 test (Table 2). We found no
relationship between pre-transplant isohaemagglutinin titre
and the risk of developing PRCA (Table 3).
Discussion
Our observations differ from previous reports which,
although controversial, hold that reduction of antidonor
isoagglutinin levels in the recipient seems to enhance
engraftment of RBC precursors. Furthermore, there are
no studies directly comparing the policies of reducing
incompatible titres vs not reducing them, pre-transplant.
Analysis of data in this series shows that the development
of PRCA is not related to pre-transplant isohaemagglutinin
levels. In our centre, all patients undergoing major ABO-
mismatched BMT or PBSCT received donor group plasma
if the titres were greater than 1:64. This policy does not,
however, seem to have made any difference to the incidence
of PRCA. This is in contrast to the data reported earlier
that the policy of reducing incompatible titres resulted in a
zero incidence of PRCA. We conclude that pre-transplant
incompatible isohaemagglutinin titres do not correlate with
PRCA post-transplant, nor does reduction of these titres
with incompatible plasma make any difference to the
incidence of PRCA. The graft source, whether PBSC or
bone marrow, does not have any effect on the risk of
developing PRCA in ABO-incompatible transplantation.
Table 1 Patient characteristics
PRCA (n¼ 15) Non-PRCA
(n¼ 68)
Baseline saline agglutination
titre
1:128 (2–512) 1:128 (4–1024)
Baseline IAT titre 1:512 (4–2048) 1:256 (16–2048)
No. received plasma 9/15 (60%) 45/68 (66%)
Volume of plasma (ml/kg) 47 (21–70) 44 (12–128)
Post-plasma infusion saline
agglutination titre
1:32 (2–1024) 1:32 (2–1024)
Post-plasma infusion IAT titre 1:256 (4–1024) 1:128 (4–2048)
Table 2 PRCA by source of stem cells
BM¼ 70 PBSC¼ 13
PRCA* (15) 10 (14.3%) 5 (38.4%)
Received plasma (9) 7/10 2/5
Non-PRCA (68) 60 8
Received plasma (45) 42/60 3/8
*P¼ 0.057.
Table 3 Antibody titres and incidence of PRCA (pre infusion of
plasma)
Antibody
titres
Number of
patients
No. with PRCA
incidence and %
P-value
Titres p1:128 38 6 (15.7%) 0.61 NS
Titres 41:128 45 9 (20%)
Titres p1:64 19 5 (26.3%) 0.28 NS
Titres 41:64 64 10 (15.6%)
Titres p1:32 11 1 (9.1%) 0.40 NS
Titres 41:32 72 14 (19.4%)
Haemagglutinin titre decrease and PRCA in ABO-mismatched BMT
S Damodar et al
234
Bone Marrow Transplantation
References
1 Petz LD. Immunohematologic problems associated with bone
marrow transplantation. Transfus Med Rev 1987; 1: 85–100.
2 Mielcarek M, Leisenring W, Tork-Storb B, Storb R. Graft
versus host disease and donor directed haemagglutinin titres
after ABO-mismatched related and unrelated marrow allo-
grafts: evidence for a graft versus plasma cell effect. Blood
2000; 96: 1150–1156.
3 Eastlund T. The histo-blood group ABO system and tissue
transplantation. Transfusion 1998; 38: 975–988.
4 Stussi G, Seebach L, Muntwyler J et al. Graft versus host
disease and survival after ABO incompatible allogeneic bone
marrow transplantation: a single center experience. Br J
Haematol 2001; 113: 251–253.
5 Bensinger WI, Buckner CD, Thomas ED et al. ABO incompa-
tible marrow transplants. Transplantation 1982; 33: 427–429.
6 Mehta J, Powles R, Horton C et al. The relationship between
donor recipient blood group incompatibility and serum bilirubin
after allogeneic bone marrow transplantation from HLA
identical siblings. Bone Marrow Transplant 1995; 15: 853–858.
7 Sniecinski IJ, Olen L, Petz LD, Blume KG. Immunohaema-
tologic consequences of major ABO mismatched bone marrow
transplantation. Transplantation 1988; 45: 530–534.
8 Gmur JP, Burger J, Schaffner A et al. Pure red cell aplasia of
long duration complicating major ABO incompatible bone
marrow transplantation. Blood 1990; 75: 290–295.
9 Benjamin RJ, Connors JM, McGurk S et al. Prolonged
erythroid aplasia after major ABO mismatched transplant-
ation for chronic myelogenous leukemia. Biol Blood Marrow
Transplant 1998; 4: 151–156.
10 Bar BM, Van Dijk BA, Schattenberg A et al. Erythrocyte
repopulation after major ABO incompatible transplantation
with lymphocyte depleted bone marrow. Bone Marrow
Transplant 1995; 16: 793–799.
11 Lee JH, Lee KH, Kim S et al. Anti-A isoagglutinin as a risk
factor for the development of pure red cell aplasia after major
ABO incompatible allogeneic bone marrow transplantation.
Bone Marrow Transplant 2000; 25: 179–184.
12 Bensinger WI, Buckner CD, Clift AR, Thomas ED. Plasma
exchange and plasma modification for the removal of anti-red
cell antibodies prior to ABO incompatible marrow transplant.
J Clin Apheresis 1987; 3: 174–177.
13 Gale RP, Feig S, Ho W et al. ABO blood group system and
bone marrow transplantation. Blood 1977; 50: 185–194.
14 Tichelli A, Gratwohl A, Wenger R et al. ABO incompatible
bone marrow transplantation: in vivo adsorption, an old
forgotten method. Transplant Proc 1987; 19: 4632–4637.
15 Stussi G, Muntwyler J, Passweg JR et al. Consequences of
ABO incompatibility in allogeneic hematopoietic stem cell
transplantation. Bone Marrow Transplant 2002; 30: 87–93.
16 Buckner CD, Clift RA, Sanders JE et al. ABO incompatible
marrow transplants. Transplantation 1978; 26: 233–238.
17 Bensinger WI, Buckner CD, Clift AR. Whole blood immuno
adsorption of anti-A or anti-B antibodies. Vox Sang 1985; 48:
357–361.
18 Nussbaumer W, Kilga S, Thaler J et al. Prevention of acute
hemolysis in transplanting ABO incompatible bone marrow.
Onkologie 1991; 14: 117.
19 Weisneth M, Hertenstein B, Bunjes D et al. ABO incompatible
bone marrow transplantation. Beitr Infusionther 1992; 30:
354–358.
20 Hocker P, Pittermann E. Plasma exchange in haematological
disorders. J Wien Klin Wochenschr 1985; 3: 115–122.
21 Slave I, Urban C, Schwinger W et al. ABO incompatible bone
marrow transplantation: prevention of hemolysis by alkaline
hydration with mannitol diuresis in conjunction with red cell
reduced buffy coat bone marrow. Wien Klin Wochenschr 1992;
104: 93–96.
22 Braine HG, Sensenbrenner LL, Wright SK et al. Bone marrow
transplantation with major ABO blood group incompatibility
using erythrocyte depletion of marrow prior to infusion. Blood
1982; 60: 420–425.
23 Dinsmore RE, Reich LM, Kapoor N et al. ABH incom-
patible bone marrow transplantation: removal of erythro-
cytes by starch sedimentation. Br J Haematol 1983; 54:
441–449.
24 Schanz U, Gmur J. Rapid and automated processing of bone
marrow grafts without Ficoll density gradient for transplant-
ation of cryopreserved autologous or ABO incompatible
allogeneic bone marrow. Bone Marrow Transplant 1992; 10:
507–513.
Haemagglutinin titre decrease and PRCA in ABO-mismatched BMT
S Damodar et al
235
Bone Marrow Transplantation
